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Background: With over 1.3 billion people, India is estimated to contain three times more genetic diversity than
does Europe. Next-generation sequencing technologies have facilitated the understanding of diversity by enabling
whole genome sequencing at greater speed and lower cost. While genomes from people of European and Asian
descent have been sequenced, only recently has a single male genome from the Indian subcontinent been
published at sufficient depth and coverage. In this study we have sequenced and analyzed the genome of a South
Asian Indian female (SAIF) from the Indian state of Kerala.
Results: We identified over 3.4 million SNPs in this genome including over 89,873 private variations. Comparison of
the SAIF genome with several published personal genomes revealed that this individual shared ~50% of the SNPs
with each of these genomes. Analysis of the SAIF mitochondrial genome showed that it was closely related to the
U1 haplogroup which has been previously observed in Kerala. We assessed the SAIF genome for SNPs with health
and disease consequences and found that the individual was at a higher risk for multiple sclerosis and a few other
diseases. In analyzing SNPs that modulate drug response, we found a variation that predicts a favorable response to
metformin, a drug used to treat diabetes. SNPs predictive of adverse reaction to warfarin indicated that the SAIF
individual is not at risk for bleeding if treated with typical doses of warfarin. In addition, we report the presence of
several additional SNPs of medical relevance.
Conclusions: This is the first study to report the complete whole genome sequence of a female from the state of
Kerala in India. The availability of this complete genome and variants will further aid studies aimed at
understanding genetic diversity, identifying clinically relevant changes and assessing disease burden in the Indian
population.
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reproduction in any medium, provided the orgenome in less than two weeks at a cost of USD ~5000
or less, whereas the human genome project took over a
decade and USD ~3 billion to complete. This advance
has paved the way for obtaining personal human gen-
omes quickly and inexpensively. Comparison of personal
genomes and select regions of the genomes against the
reference genome has provided a comprehensive view of
human genetic diversity [1]. Rapid advances in sequen-
cing technologies have enabled the identification of rare
disease risk alleles and facilitated the practice of perso-
nalized medicine when making treatment decisions,
though such applications are at their infancy [2-8].td. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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represent individuals of European ancestry [9-13]. Genomes
of individuals representing the Yoruba West-African, Han
Chinese, South Korean, Khoisan and Bantu of Africa,
Japanese, and Australian aborigines have also been pub-
lished [14-19]. Recently, an Indian male genome was also
published [20]. While a few studies have been conducted to
understand the genetic diversity across populations in
India, none have catalogued genetic variation at the whole
genome level of a female individual from the subcontinent
[20-22]. Understanding the extent of variations in the
Indian population will be important for identifying clinically
relevant changes in the Asian Indian subcontinent context.
Using a massively parallel sequencing approach, we
have obtained the complete sequence of a South Asian
Indian female (SAIF) genome. We identified over 3.4
million SNPs from this genome of which over 89,000
were found to be private SNPs. In performing an ana-
lysis of clinically relevant variants we have identified
SNPs that indicate susceptibility to multiple sclerosis.
Results
Genome sequencing and alignment to the human reference
We generated 113.16 Gb of sequence data (1,131.56 mil-
lion paired-end reads of length 100 bp) that was aligned
to the human reference sequence (GRCh37/hg19;
2,861,343,702 non-N bases) using BWA [23]. We aligned
96.27% of the reads (99.97 Gb) to the reference sequence
resulting in an average coverage of 34.94 fold across the
genome (Table 1). The coverage depth distribution of
the sequenced genome is shown in Figure 1A along with
a Poisson distribution with the same mean value. Com-
pared to the Poisson distribution, which has been used
to model sequence data in several earlier studies, we ob-
serve that the coverage distribution has more weight on
both tails. A decrease in the average coverage with in-
creasing GC content in 50 Kb non-overlapping windows
across the whole genome was also observed (Figure 1B).
While 98.89% of the reference genome was covered by
at least five reads (required for variant calls), 99.17% of
it was covered by at least one read.
We performed a de novo assembly of reads that did
not align to the chromosomes in GRCh37, using SOAP-
denovo [24]. This generated 57,426 contigs comprisingTable 1 Sequencing and analysis statistics
Total paired-end raw reads (each of 100 bases) in million 1,131.56
Total raw bases (Gb) 113.16
Total mapped bases (Gb) 99.97
Mean mapped depth (x) 34.94
Bases accessed (% of genome) 99.17
Total SNPs 3,459,784
Total Indels 384,92623,683,357 bases with an average contig length of
412 bp. Of these, 42.69% sequences aligned to the un-
anchored contigs and chromosomes in GRCh37 and an-
other 9.25% of the sequences aligned to the alternative
human assemblies. About 33.05% of the assembled
sequences aligned to other human sequences in the NT
database, while another 3.64% of the sequences aligned
to non-human primates with an E < 10-5.
SNPs and indels
We identified a total of 3,459,784 single nucleotide var-
iants (2,087,876 heterozygous) in this genome, by com-
paring it against human reference genome assembly
(GRCh37, also known as hg19), using methods previ-
ously described [14]. The SNP calls were further vali-
dated using Illumina HumanOmni1-Quad BeadchipSNP
array data. We observed a 98.7% concordance between
the SNP calls made using the sequencing data and the
SNP array, confirming the validity of the sequencing
derived SNP calls. The single nucleotide variants identi-
fied in the SAIF genome are referred to as SNPs (relative
to the human reference genome) in the results below
and this does not include single base insertions/dele-
tions. Of the total SNPs identified, 1,679,111 (48.5%)
mapped to gene (intragenic) coding regions of the gen-
ome. Given that exons form a small part of the gene
coding region, of the total intragenic SNPs identified,
only 5.6% (94,247; 29,724 in coding exons, 25,354 in
non-coding exons, 8,651 in 5’UTR and 30,518 in 3’UTR)
mapped to them (Additional file 1: Table S1A). This is
consistent with the lower mutation rates typically
observed with coding regions of the genomes [25].
Among the SNPs in coding exons, 11,155 are synonymous
(syn) substitution that are distributed among 6,631 genes
and 11,216 are non-synonymous (non-syn) changes that
map to 6,279 genes. This is consistent with a non-syn:syn
(dN/dS) ratio of ~1 expected of a normal genome [26]. Of
the SNPs identified, 1,832,801 (53%) mapped to repeat
containing regions of the genome [27,28]. Further, we
found that about two-thirds of the SNPs identified in the
repeat regions were found in long interspersed elements
(LINE; 41%; majority occurring in L1 elements) or short
interspersed elements (SINE; 30%; majority occurring in
Alu elements; Figure 2, Additional file 1: Table S1B).
In addition to SNPs, insertions and deletions (indels)
are a class of variations that shape evolution of genomes
[29,30]. In the SAIF genome, of the total 384,926 indels
identified, 190,533 (49.5%) were found in gene coding
regions. As observed with SNPs, only 7,871 (4.1%) of
indels (1,591 in coding exons, 1,769 in non-coding
exons, 620 in 5’UTR and 3,891 in 3’UTR) occurred
within exons. Of the total indels, 248,309 (64.5%) were
found in repetitive regions, proportionally higher than
SNPs that occurred in this region. This very likely reflects
Figure 1 Coverage characteristics for the sequenced genome. The coverage calculations ignore potential PCR duplicates and secondary
alignments. (A) Coverage depth distribution of the sequenced genome. The y-axis indicates the fraction of the non-N bases in the reference
sequence that has a particular coverage on the x-axis. The curve in gray shows the Poisson distribution with the best fit to the distribution.
(B) GC characteristics of the aligned data. We calculate and plot the GC percentage and average depth in non-overlapping windows of 50 kbp.
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increased occurrence of indels in repeat regions [31]. Fur-
ther, it is interesting to note that while indels were pre-
dominant (34%; 85,193) in simple repeats (Figure 2,
Additional file 1: Table S1B), only 2% of the SNPs were
found in the simple repeat regions.
The presence of SNPs and indels can affect the gene
regulatory regions such as transcription factor binding
region (TFBR)/promoters and enhancer sites. We first
looked at the average enrichment of SNPs and indels
around transcriptional start sites (TSS) of known genes.
Interestingly, we observed an increased SNPs density
around TSS, suggesting an important role for variations
in modulating expression across individuals [32]. In con-
trast to SNPs, there were fewer indels downstream of
TSS (around 50 bp downstream; Figure 3). This likely
suggests a need for preserving the promoter length/
architecture around TSS. We further investigated all
conserved TFBR and enhancer sites catalogued by UCSC
genome browser [33] and VISTA enhancer browser [34],
respectively in the SAIF genome to understand the ex-
tent of variations in these regions. For TFBR, we focused
on SNPs and indels that are present within 5 kb up-
stream of the genes. We found 1,328 SNPs and 66 indels
within the TFBR and 1,732 of SNPs and 203 indels in
the enhancer sites. The top TFBR SNP containing sites
included regions adjacent to Forkhead box J2 transcrip-
tional activator protein, myocyte enhancer factor-2
involved in cellular differentiation, Brachyury protein
involved in mesoderm formation and differentiation,
CHX10 protein involved in progenitor cell proliferation
and bipolar cell determination in developing retina, and
the peroxisome proliferator-activated receptor-gamma
(PPAR-gamma) protein that regulates adipocyte differen-
tiation. In general, we found genes involved in cancer
pathways to be enriched for SNPs in their promoter
regions (FDR <= 0.05).Coding SNPs are predominant in olfactory genes
Coding SNPs (cSNPs) can lead to amino-acid substitu-
tions in proteins encoded by the genome. In the SAIF
genome, of the 22,371 cSNPs that occur in the protein
coding sequence 11,216 lead to non-synonymous
(nsSNP) substitutions (Table 2). While the synonymous
SNPs (sSNPs) map to 6,631 genes, the nsSNPs are dis-
tributed among 6,279 protein-coding genes in the gen-
ome. To understand the significance of the cSNPs, we
assessed their enrichment in KEGG pathways using
DAVID [35]. While distribution of both sSNPs and
nsSNPs was significantly enriched (FDR<= 0.05) in
ECM-receptor interaction pathway genes, only the olfac-
tory transduction pathway genes showed a statistically
significant enrichment for nsSNPs (Figure 4A, Additional
file 2: Figure S1). This is consistent with the higher levels
of polymorphism observed in human olfactory gene fam-
ily [36]. The nsSNPs included 11,107 missense substitu-
tions and 109 non-sense mutations that lead to
premature stop (Additional file 1: Table S2). Genes with
premature stop included CASP12, a cysteine protease
involved in inflammation and innate immune response,
and OR1B1, an olfactory receptor interacting with odor-
ant molecules in the nose. The CASP12 protein contains
an N-terminal caspase activation and recruitment do-
main (CARD) and a C-terminal catalytic cysteine prote-
ase domain characteristic of caspase family of proteins
(Figure 4B). The non-sense mutation observed in the
SAIF genome codes for a truncated CASP12 protein
that contains just the N-terminal CARD domain. Re-
cent re-sequencing studies have shown that this trun-
cated form of CASP12 confers resistance to sepsis
and is predominant across many populations [37-39].
Another non-sense mutation in the SAIF occurred in
the OR1B1, which encodes a G-protein coupled olfac-
tory receptor. The OR1B1 SNP leads to truncation of
the 7-transmembrane receptor domain present in
Figure 2 Annotation of SNPs and Indels. The SNPs and Indels coordinates were compared with gene boundary, exon boundary, untranslated
and protein-coding regions, repeats, repeat classes and subclasses.
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protein has been observed in a recent study [39] and
is thought to affect metabolism of serum cholinester-
ase [40]. Overall, our assessment of the effect of the
nsSNPs using SIFT [41] indicates that 1,460 are likely
damaging (Additional file 1: Table S3).
Unlike SNPs, indels in coding regions, in addition to
non-sense mutations, can lead to frame shift changes.
Of the 372 coding region indels, 172 are in-frame and
200 lead to frame-shift change (Additional file 1: Table
S4A, Additional file 1: Table S4B). Genes where the
indel leads to a frame-shift includes HIF3A, hypoxia in-
ducible factor 3 alpha subunit, thought to be a negative
regulator of hypoxia-inducible gene expression; MMP28,
a matrix metallopeptidase involved in the breakdown of
extracellular matrix for both normal physiological anddisease processes; and HNF1A, a transcription factor
required for the expression of several liver-specific genes.
The frame-shift at position 147 in MMP28 protein intro-
duces a premature stop codon at 179. This results in loss
of zinc-dependent metalloprotease and hemopexin-like
repeat domain, leading to a truncated MMP28 protein
that lacks a catalytic domain (Additional file 2: Figure
S2). SIFT analysis of the indels indicated 126 indels
to be deleterious (Additional file 1: Table S5).
Comparison and novel variants
We compared SAIF SNPs against those from other pub-
lished personal genomes, the variations from the 1000
Genomes Project and dbSNP database (dbSNP132). The
personal genomes used to perform the comparison had
a sequencing coverage of at least 10X. Shared SNP sites,
Figure 3 Average enrichment of variant around TSS of genes. (A) Average enrichment of all variants (SNPs + Indels) around TSS, (B) Average
enrichment of SNPs around TSS, (C) Average enrichment of Indels around TSS.
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pared to carry a SNP, provide a measure of the degree of
similarity between the genomes. We also compared the
indels found in the SAIF genome with those reported by
the 1000 Genomes Project.
SNPs level comparison of the SAIF genome found that
this individual shared 48.77% of the SNP sites with
NA12891 (Caucasian) genome, 48.82% with the
NA12892 (Caucasian) genome, 52.5% with the Venter
(Caucasian) genome, 50.68% with the NA18507 (YRI)
genome, 44.29% with the NA19238 (YRI) genome, 44.33%
with NA19239 (YRI), 53.75% with YH (Han Chinese) gen-
ome, 59.24% with SJK (Korean) genome, 46.5% with ABT
(South Africa) genome, 51.1% with Irish (Caucasian) gen-
ome, 49.86% with KB1 (Southern Kalahari, Africa), 59.41%
with the recently published Indian male genome [20],
95.18% with dbSNP 132, and 92.44% with 1000 Genomes








Frame-shifting Indels 200Overall, we found that 2.6% (89,873) of the SNPs and
83.83% (322,295) of the indels to be unique to SAIF gen-
ome (Figure 5, Additional file 1: Table S6). The complete
list of novel SNPs and indels is provided in Additional
file 1: Table S7. Of the novel SNPs, 22,412 (24.94%)
mapped uniquely to genes, 28,313 (31.5%) mapped spe-
cifically to repeat regions, 21,826 (24.29%) mapped to
both gene coding and repetitive regions and 17,322
(19.27%) mapped to other regions of the genome. Fur-
ther, of the total novel SNPs that mapped to coding
regions, 543 led to protein level alterations (533 mis-
sense SNPs and 10 non-sense substitutions). Genes hav-
ing novel non-sense substitutions include TSG101, a
phosphoprotein implicated in tumorigenesis and the
CD164 gene that plays a role in hematopoiesis. Further,
assessment of the protein altering novel SNPs using
SIFT predicted 154 of these to be likely damaging.
mtDNA analysis
Mitochondrial DNA (mtDNA) sequence is widely used to
understand the maternal genetic history of human popula-
tions [42]. Analysis of the SAIF mt genome showed that it
had 35 SNPs (control region 9, non-coding region 1, RNA
genes 5 and protein coding genes 20; syn/non-syn ratio of
16/4) compared to the Cambridge reference sequence
(rCRS, Figure 6). The closest mtDNA sequence of SAIF
among the mtDNA in GenBank was AY714038, belonging
to U1a3 haplogroup (Additional file 2: Figure S3). This
sequence was reported from a study involving the Indian
population [43] and contained 14 nucleotide differences
Figure 4 (A) Pathway enrichment analysis. The enriched KEGG pathways (FDR<= 0.05) identified are reported. (B) Non-sense SNP (C > T) in
codon 125 of CASP12 leads to its truncation. (C) A variant in OR1B1 gene results in a premature stop and truncation of OR1B1.
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related haplogroup with the SAIF mt genome was the
U1a3 haplogroup. This is consistent with the fact that
the SAIF individual is from the southern Indian state of
Kerala where the frequent occurrence of U1 haplogroup
has been previously reported [44]. The coalescence time
for the U1a lineage was estimated to be about 46 kya
(Additional file 2: Figure S4). This deep divergence and
genetic distance between SAIF and its closely related
haplogroups suggest that the SAIF mt genome belongs
to one of the distinctive lineages within the U1a
haplogroups.
SNPs with health and medical relevance
We assessed cSNPs identified in the SAIF genome using
annotations in SNPedia and OMIM for their health andFigure 5 Comparison of SAIF SNPs with 12 published personal
genomes, 1000 Genomes Project SNPs and dbSNP132.disease relevance. This analysis identified 59 and 63
cSNPs with implications in health and disease from
SNPedia and OMIM databases [45,46], respectively
(Additional file 1: Table S8 and Additional file 1: Table
S9). Interestingly, this analysis revealed several SNPs
with implications for susceptibility to cancer and cardio-
vascular diseases. The cancer susceptibility SNPs
included the variation in SDHB gene (S163P, OMIM_ID
#185470.0015), responsible for Cowden-like syndrome,
resulting in enrichment of carcinomas of human breast
due to downstream inactivation of PTEN [47]. We also
found an exon 10 BRCA2 variant (N372H; OMIM_ID #
600185.0133), [48] and an EPCAM variant identified in
Chinese population (M143T; rs1126497; [49]) that are
associated with increased risk for breast cancer. Further,Figure 6 Graphical representation of SAIF mitochondrial (mt)
genome in comparison to Cambridge reference sequence
(rCRS). Vertical bar in the individual mt genomes indicates SNP
positions in comparison to rCRS. The SAIF mt DNA has 35 SNPs
compared to rCRS. The closest haplotype of the SAIF sequence, the
U1a3 Haplotype (AY714038) has 37 SNPS compared to rCRS. The
Korean mt DNA [16] has 40 SNPs and the KB1 southern African [14]
had 80 SNPs in comparison to rCRS.
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the SAIF genome is associated with a poor breast cancer
survival [50]. Other SNPs with increased cancer suscepti-
bility include FCGR2A H166R (rs1801274) associated
with increased risk for non-Hodgkin’s lymphoma [51],
ANKK1 E713K (rs1800497; [52]) involved in advanced
adenoma recurrence, HNF1A S487N (rs2464196; [53]),
MMP9 Q166R (rs17576-rs2250889; [54]), and XPC
Q939K (rs2228001; [55]) variants associated with lung
cancer, ATG16L1 T137A (rs2241880; [56,57]) with
Crohn’s disease, and OGG1 P332A (rs1052133; [58-60])
associated with bladder and gall-bladder cancer in Japa-
nese, Chinese and Indian populations. An ATR (M211T;
rs2227928) variant found in the genome has been asso-
ciated with a poorer response to gemcitabine and radi-
ation therapy in pancreatic cancer [61]. We also found a
protective SNP that occurs in the PON1 gene (Q192R;
rs662) that is known to lower (0.65x) risk for ovarian
cancer [62]. Two common missense variations in ELAC2
gene (A541T; OMIM_ID # 605367.0002 and S217L;
OMIM_ID # 605367.0001) implicated in genetic suscep-
tibility to heredity prostate cancer were found in the
SAIF genome. This while not of direct significance to
SAIF individual, could be of relevance to the male chil-
dren, if any [63-65].
The cardiovascular disease associated SNPs found in
this individual include those in LRP8 (R952Q; rs5174/
OMIM_ID # 602600.0001; [66]) and MMP9 (Q166R;
rs17576; [67]) both of which increase risk for myocardial
infarction, ROS1 (S2229C; rs619203; [68]) variation
associated with increased coronary heart disease,
AKAP10 SNP (I646V; OMIM_ID # 604694.0001; [69])
associated with cardiac conductivity defect susceptibility
and ADRB3 variant (W64R; rs4994; [70]) implicated in
higher risk of cardiac events. Also, two SNPs in the
PON1 (Q192R; rs662 and L55M; rs854560) show a high
risk of cardiovascular disease [71] and a higher risk of
coronary artery disease [72,73]. A SNP in SNX19
(L878R; rs2298566) is linked to elevated risk of coronary
heart disease but has also been shown to be associated
with better response to statins and may be of clinical sig-
nificance [74]. Other SNPs affecting cholesterol levels
(EDN1 K198N; OMIM_ID # 131240), familial obesity
(FAM71F1 E143K; rs6971091) and hypertension suscep-
tibility (PPARFC1A, G482S; rs8192678 and CYP4A11,
F434S; rs1126742) were also found in the genome.
In addition to this, several other SNPs associated with
Alzheimer’s disease, diabetes, tuberculosis susceptibility
and macular degeneration were also detected. A SNP in
ICAM1 (K469E; rs5498), associated with increased re-
sistance to malarial infection, originally identified in a
study of over 552 Indian individuals [75], was also
observed in the SAIF genome. It must be noted that a
majority of the SNPs of health relevance used toannotate the coding SNPs were derived from studies in-
volving western populations. Hence, validating the rele-
vance of these in the context of Asian Indian population
will require controlled studies in a cohort representative
of the Indian subcontinent.
Besides assessing the cSNPs using SNPedia and
OMIM, we performed a comprehensive assessment of
predicted genetic risk of the SAIF genome for 49 dis-
eases using Varimed [76]. As described recently [77],
we first estimated the pre-test probability using the
prevalence of each disease according to the age, gen-
der, and ethnicity of SAIF. Using this analysis of the
SAIF genome we found 17 diseases that had post-test
probability >5% (Figure 7).
We further assessed the relative genetic risk of SAIF
against Gujarati Indians in Houston (GIH) population
represented in HapMap III. We used the set of disease
SNPs measured in both SAIF and GIH, and recalculated
the likelihood ratio (LR) for SAIF and each of 101 GIH
individuals. We found that the SAIF individual had a
higher genetic risk than 80% of GIH for eight diseases
(Additional file 2: Figure S5). Intersecting both results, we
found that SAIF had a high genetic risk for four diseases,
including multiple sclerosis (post-test probability = 5%,
relative risk> 100% GIH), uterine leiomyoma (post-test
probability = 47%, relative risk > 97% GIH), asthma (post-
test probability = 17%, relative risk > 90% GIH), and obesity
(post-test probability = 34%, relative risk > 82% GIH).
SAIF’s high genetic risk on multiple sclerosis is
based on a rare heterozygous AG variant at
rs3135388 in HLA-DRA (Figure 8), which appears in
4% GIH individuals. Multiple studies have linked the
presence of the “A” allele with an increased risk for
multiple sclerosis in American, Australian, British,
Canadian, Dutch, mixed European, and Serbian popu-
lations [78-87]. International Multiple Sclerosis Genet-
ics Consortium used this allele as a proxy for the
DRB1*1501 allele, which had been demonstrated as a
causal variant for multiple sclerosis and validated in
animal models in OMIM (OMIM_ID #126200). This
variant has also been validated as a functional regula-
tory variant, with evidence from transcription factor
binding site, eQTL, and DNase peak from Regulome
DB (http://www.regulomedb.org/) with data from
ENCODE.
In addition to multiple sclerosis, SAIF had a high
genetic risk of uterine leiomyoma, driven by a rare het-
erozygous CT variant at rs7913069 (Additional file 2:
Figure S6). The T allele had been validated to increase the
risk of uterine leiomyoma with an odds ratio of 1.47 and
p-value= 8.65 × 10-14 in Japanese women [88]. A high gen-
etic risk for asthma and obesity were also identified in the
SAIF individual [89,90] (Figure 8, Additional file 2: Figures
S7 and Additional file 2: Figures S8).
Figure 7 RiskOgram for 49 diseases. For each disease, the arrow represents the pretest probability according to the subject’s age, gender, and
ethnicity. The line represents the post-test probability after incorporating the subject’s genome sequence. Orange line represents increased
genetic risk, while blue line represents decreased genetic risk. Listed to the right are the numbers of independent disease-associated SNPs used
to calculate the subject’s post-test probability.
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An individual’s SNPs can be used to predict adverse drug
reactions and also manage the dose of drugs prescribed.
In order to understand SNPs of pharmacogenomic rele-
vance, we evaluated SAIF variants using annotations
present in the PharmGKB database [91] and a set of
published SNPs relevant for drug interactions. We iden-
tified 109 SNPs with pharmacogenomic relevance based
on PharmGKB (Additional file 1: Table S10). We identi-
fied 10 actionable SNPs from literature as it pertains to
treatment with various drugs, some of which are also
represented in the PharmGKB (Table 3). As India has a
high burden of diabetes, we looked at the SAIF genome
for a SNP in ATM previously associated with metformin
response [92]. Metformin is a drug widely prescribed to
manage blood sugar levels in diabetics. We found a GG
(rs4585) variant in ATM in the SAIF genome and this is
associated with positive response to metformin [92].
FDA in the US has recommended testing for SNPs that
help in deciding the dosage of warfarin, used as a bloodthinner. Based on the three SNPs (Table 3) found in the
SAIF genome, we conclude that a typical dose of war-
farin is not likely to cause bleeding. Given that the SAIF
genome SNPs predicted an increased risk for multiple
sclerosis, we looked at genes with SNPs that predict re-
sponse to therapy in the context of multiple sclerosis.
We found a CT variant (rs7987675) in GPC5, which is
associated with typical response to beta interferon therapy
in relapsed multiple sclerosis patients. Besides these
expected drug responses, we have identified additional ones
based on the SAIF genome and they are detailed in Table 3.
Discussion
We have sequenced the genome of a female from Kerala
in southern India and identified 3,459,784 SNPs and
384,926 short indels. Comparison with published per-
sonal genomes revealed that SAIF shared ~50% of the
SNPs with each of the personal genomes published so
far and had 89,873 private SNPs. Of the total SNPs
detected, we identified 11,107 missense substitutions and
Figure 8 Contribution of individual SNPs to overall risk for (A) multiple sclerosis and (B) obesity. Single nucleotide polymorphisms (SNPs)
with associations established from genome-wide association shown in decreasing order of number of studies showing association for a given
SNP. An increasing shade of black filling squares corresponding to each SNP on the graph is indicative of the number of studies that reports a
disease association for that SNP. The size of boxes is proportional to the logarithm of the number of samples used to calculate the likelihood
ratio (LR). The post-test probabilities were computed using the pre-test estimate as a starting point. An updated combined post-test risk
probability is shown along the y-axis that includes the contribution of indicated SNP and those above it on the graph. *Gene names are shown
where the SNP lies in an annotated gene region. +Number of studies reporting an association. #Number of samples used to calculate the LR.
GIH- The frequency of a SNP in the Gujarati Indian Population from the Varimed database is also shown.
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http://www.biomedcentral.com/1471-2164/13/440109 non-sense mutations. We found olfactory genes to
be enriched for non-synonymous SNPs suggesting that
this family of genes may be under reduced evolutionary
constraint in humans. Besides the nuclear genome, ana-
lysis of the mitochondrial genome showed that SAIF
mitochondria belonged to the U1 haplogroup which is
known to occur in the southern Indian state of Kerala.
SNPs in personal genomes can be used to assess dis-
ease risk, carrier status and drug response/interaction.
We have assessed the SAIF genome using OMIM, SNPe-
dia and Varimed databases for SNPs with health and dis-
ease consequences. We identified higher risk for
multiple sclerosis, among other diseases. Drug response
related SNP assessment revealed that the SAIF genome
carried a SNP in the ATM gene that predicts a favorable
response to metformin used in treating diabetes. These
and the other annotations made using experimentally
verified variants will very likely be used by physicians for
counseling and making treatment decisions.A recent study on variations in India using SNP array
suggest that genetic diversity within India is at least
three times that observed within Europe [22]. In India,
burden of recessive genetic disorders is predicted to be
high and likely to be unique within each population
group [93]. Additional personal genomes from Indian
subcontinent that represent population groups within
India will be critical to assessing the variation and dis-
ease burden.
Conclusions
In this study we report the first complete sequence of a
south Asian Indian female from the state of Kerala in
India. The availability of this genome and the variants
identified is a first step in understanding the genetic di-
versity in the Indian subcontinent. In addition, the clin-
ically relevant changes identified in this personal
genome, along with further studies on additional gen-
omes from this region, should provide a comprehensive
Table 3 Drug response SNPs
# Drug/Condition Chromosomal
location
Gene Genotype SNP-ID Drug related outcome
1 Interferon beta therapy for
multiple sclerosis (MS)
chr13:92884370 GPC5 CT rs7987675 will likely not show increase response to




chr6:32305978 C6orf10 GT rs3129900 increase in liver toxicity risk in response to
lumiracoxib used to treat acute pain and
osteoarthritic symptoms
3 Metformin Response chr11:108239628 ATM-C11orf65 GG rs4585 will respond better to Metformin
4 Ribavirin-induced anemia chr20:3193842 ITPA CA rs1127354 greatly decreased odds of developing anemia
when taking PEG-IFN/RBV
5 Statin induced myopathy chr12:21331549 SLCO1B1 TT rs4149056 typical dose of Simvastin will not increase
myopathy risk
6 Floxacillin and liver
toxicity
chr6:31431780 HCP5 TT rs2395029 at typical dose liver toxicity is not expected
in response to floxacillin
7 Beta-Blocker - heart failure
risk
chr10:115805056 ADRB1 CC rs1801253 Bucindolol is unlikely to reduce mortality
odds in case of heart failure
8 Response to amitriptyline chr7:87160561 ABCB1 AA rs2032583 typical response to depression when treated
with Elavil, Paxil, Effexor, or Celexa
9 Warfarin sensitivity chr10:96702047 CYP2C9 CC rs1799853 typical dose of warfarin does not increase
risk of bleeding
chr10:96741053 CYP2C9 AA rs1057910
chr16:31107689 VKORC1 CC rs9923231
promoter
10 Fluorouracil toxicity chr1:97915613 DPYD CC rs3918290 No copies of the DPYD*2A mutation. May still
be at risk for 5-FU toxicity due to other
genetic or non-genetic factors
Gupta et al. BMC Genomics 2012, 13:440 Page 10 of 14
http://www.biomedcentral.com/1471-2164/13/440assessment of the disease burden in the Indian
population.Methods
Sample collection, library construction and sequencing
Informed consent was obtained from the individual prior
to initiation of this study. The donor is a healthy 48 year
old female from Kerala in the southern part of India.
Blood sample (8.5 ml) was collected in a PAXgene Blood
DNA Tube (Qiagen, CA) and processed as per manufac-
turer’s instructions. High molecular weight genomic
DNA obtained was sheared and used in the preparation
of the whole genome shotgun libraries as per Illumina’s
library preparation protocols (Illumina, CA). The librar-
ies were then sequenced on a HiSeq 2000 sequencing
machine (Illumina, CA) to obtain the sequence data.Alignment to the reference
We used BWA (version 0.5.9) to align the reads to the
human reference sequence (GRCh37/hg19). All default
parameters were used, with the exception of “-q 15”
which allows read trimming at the 3’ ends, down to
35 bp, prior to alignment. Potential PCR duplicates,
which can adversely affect the variant calls, were
removed using the MarkDuplicates tool from Picardversion 1.4.0 (http://picard.sourceforge.net). The result-
ing BAM file was used for all subsequent analysis.
De novo assembly of unaligned reads
We used SOAPdenovo with a K-mer size of 39 and with
the “-R” option to use reads to solve tiny repeats. The
resulting contigs were first aligned to unanchored con-
tigs in hg19 using LASTZ requiring an identity > 95%
and requiring more than 80% of the assembled contig
sequence in the alignment. The reads that did not align
to hg19 were compared using BLAST [94] against all
existing human assemblies using BLASTN requiring an
E < 10-5. The remaining reads were then analyzed using
BLAST against the NT database.
SNP and Indel identification
We used SAMtools (version 0.1.12a) to call variants
(substitutions and small indels) from the alignments
generated above. All default parameters were used in
conjunction with “-C 50” to reduce the effects of the
sequences with excessive mismatches. The variants were
filtered to keep the ones where the depth of coverage
was > = 5 and < = 60 for all chromosomes except the
mitochondria. A total of 3,620,895 single nucleotide sub-
stitutions and 509,994 indels were identified in this sam-
ple, and we further filtered the variants to only keep the
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variants that did not share any alleles with the reference
sequence were excluded. The SNP calls made using the
whole genome sequencing data were further validated
using SNP calls for this individual derived using Illumina
HumanOmni1-Quad Beadchip SNP array. We found
that the calls between sequencing data and the SNP to
be concordant at 989,747 of 1,003,031 SNP array posi-
tions (98.7% concordance).SNP and Indel annotation
We designed a pipeline to annotate SNPs and indels.
The human gene annotation release 62 provided by
Ensembl database (http://www.ensembl.org/info/data/
ftp/index.html) was used for annotating variants with
gene, exon and UTRs. The repeat definition, conserved
TFBS and enhancer information was obtained from
UCSC genome browser database (http://genome.ucsc.
edu). SIFT annotation was performed using the online
version available at (http://sift.bii.a-star.edu.sg/). The
pathway analysis was performed using DAVID program
[35] and an FDR of < = 0.05 was used to identify signifi-
cant pathways.Comparison and novel variants
The personal genome information was obtained from
Ensembl, UCSC, Galaxy and published articles. The vari-
ant annotation for 1000 Genomes Project was obtained
from (http://www.1000genomes.org/). The common
SNP database (dbSNP132) was downloaded from
Ensembl and UCSC. Liftover program (http://genome.
ucsc.edu/cgi-bin/hgLiftOver) was used to convert the
coordinate from hg18 to hg19 version of the genome.mtDNA analysis
From the comparison of the SAIF mt genome and the
reference sequence (rCRS, NC_012920), 35 single nu-
cleotide variants were found. Those variants were used
to identify the haplotype of SAIF, using Haplogrep [95].
To examine phylogenetic relationships of the haplotype
of SAIF with closely related haplotypes, the Neighbor-
Joining tree was constructed by MEGA5 [96] for 210
complete mitochondrial genomes belonging to U and K
haplogroups. The genome sequences were retrieved
from GenBank. The coalescence time for the U hap-
logroups was estimated using BEAST [97]. For the
BEAST analysis, 313 mt genome sequences evenly dis-
tributed throughout all lineages obtained from GenBank
were used. The following parameters were used for the
BEAST analysis: strict clock molecular clock model, ex-
ponential growth tree prior, Markov chain Monte Carlo
(MCMC) chain length 2 M, and 10% burn-in.OMIM, SNPedia and varimed annotation
We compared the SNPs predicted from the SAIF gen-
ome against disease associated OMIM variants. We also
annotated the SAIF genome against SNPedia to under-
stand the effect of the variants. Annotation using
Varimed database was performed as described recently
[77]. Briefly, we first retrieved the SAIF’s genotypes, in-
cluding variants and ref-ref calls for all the significant
SNPs represented in the Varimed database known to be
associated with disease based on genome-wide associ-
ation studies. For multiple SNPs in the same linkage dis-
equilibrium with R2 > 0.3, we only kept the one with the
strongest evidence. Finally, we multiplied the likelihood
ratio (LR) from independent SNPs, incorporated it with
the pre-test probability to estimate the post-test prob-
ability of the disease.Additional files
Additional file 1: Table S1. SNPs and indels in (A) Gene, Regulatory
and Enhancer regions, (B) Repeat class and family. Table S2 Non-
synonymous SNPs in SAIF genome. Table S3 SNPs predicted to be
damaging by SIFT. Table S4 (A) In-frame short indels, and (B) Short
frameshift indels in SAIF genome. Table S5 Short indels predicted to lead
to non-sense mediated decay (NMD) by SIFT. Table S6 SAIF SNP
comparison. Table S7 Novel SNPs and indels in SAIF genome. Table S8
SAIF SNPs represented in OMIM. Table S9 SAIF SNPs annotated using
SNPedia. Table S10 Pharmcogenomic relevant variants in SAIF genome.
Additional file 2: Figure S1. Pathway analysis of synonymous SNPs.
Pathway enrichment analysis was performed using DAVID program. The
enriched KEGG pathways (FDR<= 0.05) identified are reported. Figure S2.
Protein domain position and non-sense SNP location in MMP28 protein.
Figure S3. Phylogenetic relationship of the SAIF mt genome. The tree on
the left shows phylogenetic relationships of human mt macro-
haplogroups. The right tree is a Neighbor-Joining tree of U and K
haplogroups. The tree was constructed using 210 complete mt genome
sequences, which were obtained from the GenBank database, including
the SAIF mt genome (highlighted by red). The SAIF mitochondrial
genome clustered with the U1 branch and was closely related to the
U1a3 haplogroup. A comparison of the SAIF mt genomic sequence
against the U1a3 sequence (GenBank accession # AY714038) revealed 14
nucleotide differences between the two genomes. Figure S4.
Coalescence time estimations for the U haplogroup. The coalescence
time for the U mt haplogroup was estimated by the BEAST analysis [97].
A total of 313 mt complete genome sequences obtained from GenBank
that are representative of each macro-haplogroup and each U1
haplogroup were used in the analysis. We calibrated our time to most
recent common ancestor (TMRCA) estimates based on published
estimate of 660 kya for the separation of the Homo sapiens and
Neanderthal mt lineages [98] and the 194.3 ± 32.55 kya TMRCA estimate
for the global mtDNA genome tree [99]. BEAST analysis was run with
HKY substitution model, the strict molecular clock model, exponential
population growth tree prior, MCMC chain length 2M, and a 10% burn-in,
as parameters. The coalescence time for the U haplogroup and U1a
haplogroup were estimated to be 86 kya and 46 kya, respectively.
Figure S5. Relative genetic risk of SAIF in comparison to GIH population
represented in HapMap III. We used a set of disease SNPs measured in
both SAIF and GIH, and recalculated the LR for SAIF and each of 101 GIH
individuals. The histogram of the individual in each risk range is shown
for each disease. SAIF individual had a higher genetic risk than 80% of
GIH on eight diseases. Figure S6. Contribution of individual SNPs to the
overall risk for uterine lyoma is shown. For explanation of the symbols
and other parameters in the graph refer to Figure 8.
Figure S7. Contribution of individual SNPs to the overall risk for asthma
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http://www.biomedcentral.com/1471-2164/13/440is shown. For explanation of the symbols and other parameters in the
graph refer to Figure 8. Figure S8. Contribution of individual SNPs to the
overall risk for obesity is shown. For explanation of the symbols and
other parameters in the graph refer to Figure 8.
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